BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moessner BK, Jørgensen TR, Skamling M, Vyberg M, Junker P, Pedersen C, Christensen PB. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011;106:970-6. [PMID: 21182552 DOI: 10.1111/j.1360-0443.2010.03246.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20-30. [PMID: 30157316 DOI: 10.1111/liv.13949] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
2 Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. [PMID: 28683982 DOI: 10.1016/j.drugpo.2017.05.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
3 van Santen DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, van der Valk M, Prins M. High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands. Eur J Gastroenterol Hepatol 2018;30:1168-76. [PMID: 30028776 DOI: 10.1097/MEG.0000000000001213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dolman GE, Nieboer D, Steyerberg EW, Harris S, Ferguson A, Zaitoun AM, Ryder SD, James MW, Aithal GP, Guha IN. The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value? Liver Int 2013;33:172-9. [DOI: 10.1111/liv.12017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ; International Network for Hepatitis in Substance Users. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:893-898. [PMID: 26254497 DOI: 10.1016/j.drugpo.2015.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
6 Lindvig K, Mössner BK, Pedersen C, Lillevang ST, Christensen P. Liver stiffness and 30-day mortality in a cohort of patients admitted to hospital: LIVER STIFFNESS AND SHORT-TIME MORTALITY. European Journal of Clinical Investigation 2012;42:146-52. [DOI: 10.1111/j.1365-2362.2011.02571.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
7 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. Int J Drug Policy 2015:S0955-3959(15)00351-5. [PMID: 26847504 DOI: 10.1016/j.drugpo.2015.11.009] [Reference Citation Analysis]
8 Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res. 2014;104:62-72. [PMID: 24468275 DOI: 10.1016/j.antiviral.2014.01.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
9 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
10 Treloar C, Rance J, Dore GJ, Grebely J; the ETHOS Study Group. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. J Viral Hepat 2014;21:560-7. [DOI: 10.1111/jvh.12183] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
11 Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One 2014;9:e111912. [PMID: 25369038 DOI: 10.1371/journal.pone.0111912] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
12 Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. The Lancet Gastroenterology & Hepatology 2017;2:288-97. [DOI: 10.1016/s2468-1253(16)30205-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 44] [Article Influence: 19.4] [Reference Citation Analysis]
13 Thurnheer MC, Schulz TR, Nguyen T, MacLachlan J, Sasadeusz J. Regional challenges: evaluation of a hepatitis outreach programme using transient elastography (FibroScan) in Victoria. Intern Med J 2016;46:273-81. [PMID: 26602052 DOI: 10.1111/imj.12963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Marshall AD, Grebely J, Dore GJ, Treloar C. ‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy 2017;47:153-60. [DOI: 10.1016/j.drugpo.2017.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
15 Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell DL, Wilson JA. Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol Hepatol 2016;2016:5743521. [PMID: 27446849 DOI: 10.1155/2016/5743521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Sækmose SG, Mössner B, Christensen PB, Lindvig K, Schlosser A, Holst R, Barington T, Holmskov U, Sorensen GL. Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort. PLoS One 2015;10:e0140418. [PMID: 26460565 DOI: 10.1371/journal.pone.0140418] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
17 Crowley D, Cullen W, Laird E, Lambert JS, Mc Hugh T, Murphy C, Van Hout MC. Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic. J Transl Int Med 2017;5:112-9. [PMID: 28721344 DOI: 10.1515/jtim-2017-0017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
18 Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S129-S137. [PMID: 23884061 DOI: 10.1093/cid/cit302] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
19 . Corrigendum: Corrigenda. Addiction 2012;107:236-236. [DOI: 10.1111/j.1360-0443.2011.03726.x] [Reference Citation Analysis]
20 Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, Jones SC, Bath N, How-Chow D, Byrne J, Harvey P, Dunlop A, Jauncey M, Read P, Collie T, Dore GJ, Grebely J. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy 2015;26:984-91. [PMID: 26256938 DOI: 10.1016/j.drugpo.2015.07.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
21 Harris R, Card TR, Delahooke T, Aithal GP, Guha IN. The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. United European Gastroenterol J 2018;6:1372-9. [PMID: 30386610 DOI: 10.1177/2050640618772944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
22 Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy 2017;47:26-33. [DOI: 10.1016/j.drugpo.2017.08.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
23 Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, Sutherland L, Clement F. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol 2013;27:149-58. [PMID: 23516679 DOI: 10.1155/2013/684982] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
24 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ. Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. International Journal of Drug Policy 2015. [DOI: 10.1016/j.drugpo.2015.11.011] [Reference Citation Analysis]
25 Arain A, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, Buntinx F, Robaeys G. Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs. J Subst Abuse Treat 2016;67:44-9. [PMID: 27296661 DOI: 10.1016/j.jsat.2016.04.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
26 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. Int J Drug Policy 2015:S0955-3959(15)00352-7. [PMID: 26749563 DOI: 10.1016/j.drugpo.2015.11.010] [Reference Citation Analysis]
27 Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS. 2011;6:501-507. [PMID: 22001894 DOI: 10.1097/coh.0b013e32834bcb36] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
28 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:1028-38. [PMID: 26282715 DOI: 10.1016/j.drugpo.2015.07.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 18.1] [Reference Citation Analysis]
29 Mohamed Z, Rwegasha J, Kim JU, Shimakawa Y, Poiteau L, Chevaliez S, Bhagani S, Taylor-Robinson SD, Thursz MR, Mbwambo J, Lemoine M. The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. J Viral Hepat 2018;25:1438-45. [PMID: 29974582 DOI: 10.1111/jvh.12966] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
30 Bouscaillou J, Champagnat J, Luhmann N, Avril E, Inaridze I, Miollany V, Labartkava K, Kirtadze I, Butsashvili M, Kamkamidze G, Pataut D. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment. Int J Drug Policy 2014;25:871-8. [PMID: 24529802 DOI: 10.1016/j.drugpo.2014.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
31 Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. International Journal of Drug Policy 2017;47:34-46. [DOI: 10.1016/j.drugpo.2017.07.002] [Cited by in Crossref: 108] [Cited by in F6Publishing: 105] [Article Influence: 21.6] [Reference Citation Analysis]
32 Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 2017;14:641-51. [DOI: 10.1038/nrgastro.2017.106] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 21.4] [Reference Citation Analysis]
33 Subhani M, Harman DJ, Scott RA, Bennett L, Wilkes EA, James MW, Aithal GP, Ryder SD, Guha IN. Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour? Biomedicines 2022;10:477. [DOI: 10.3390/biomedicines10020477] [Reference Citation Analysis]
34 Christensen PB, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, Weis N, Obel N, Cowan S. Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. BMC Infect Dis. 2012;12:178. [PMID: 22866925 DOI: 10.1186/1471-2334-12-178] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
35 Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10:374-380. [PMID: 26248124 DOI: 10.1097/coh.0000000000000179] [Cited by in Crossref: 97] [Cited by in F6Publishing: 54] [Article Influence: 16.2] [Reference Citation Analysis]
36 Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat. 2012;19:829-835. [PMID: 23205675 DOI: 10.1111/jvh.12008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 6.8] [Reference Citation Analysis]
37 Mössner BK, Staugaard B, Jensen J, Lillevang ST, Christensen PB, Holm DK. Dried blood spots, valid screening for viral hepatitis and human immunodeficiency virus in real-life. World J Gastroenterol 2016; 22(33): 7604-7612 [PMID: 27672281 DOI: 10.3748/wjg.v22.i33.7604] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]